Related Experiment Video

Updated: Mar 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

Servet Altay1, Özlem Yıldırımtürk, Hüseyin Altuğ Çakmak

  • 1Department of Cardiology, Faculty of Medicine, Trakya University; Edirne-Turkey. svtaltay@gmail.com.

Anatolian Journal of Cardiology
|January 20, 2017
PubMed
Abstract

Insights

New oral anticoagulants (NOACs) are widely used for stroke prevention in non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) treatment. This study highlights increased low-dose NOAC use in Turkey, suggesting treatment guidelines are needed to optimize patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • New oral anticoagulants (NOACs) are increasingly prescribed for non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).
  • Understanding current treatment patterns and outcomes is crucial for optimizing NOAC therapy.

Purpose of the Study:

  • To evaluate current patterns of NOAC treatment in Turkey.
  • To analyze demographic, clinical parameters, and adverse events (bleeding/embolic) associated with NOAC use.

Main Methods:

  • A multicenter cross-sectional study (NOAC-TURK) involving 2,862 patients treated with NOACs for at least three months.
  • Data collected via survey and electronic health records, including demographics, clinical characteristics, and medications.

Main Results:

  • Hypertension was the most common comorbidity (81%); permanent atrial fibrillation was the primary indication (83.3%).
  • Bleeding occurred in 7.6% and embolic events in 1.3% of patients.
  • Notably, 47.6% of patients received lower-than-expected NOAC doses.

Conclusions:

  • The NOAC-TURK study provides insights into Turkish NOAC treatment practices.
  • While complications were comparable to prior studies, the high rate of low-dose NOAC use warrants attention.
  • Treatment guidance using CHA2DS2-VASc and HASBLED scores is recommended for NVAF patients to maximize benefits and minimize risks.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
305
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
196
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
406